Prenetics reports Q3 cont ops EPS (7c) vs. (25c) last year

Reports Q3 revenue $4.9M vs. $4.3M last year. “During the third quarter, we made further progress on our transformation. The recent completion of the reverse stock split also addressed any uncertainty regarding our listing status. We believe there are significant opportunities with our consumer health and clinical oncology business units, and are making investments to address these significant opportunities. With the strong cash position and a strong team, we are confident in our pathway to deliver growth and value,” said Danny Yeung, CEO and Co-Founder of Prenetics